Clinical Trial Details

Short Title
Official Title
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study

Participants in this study have acute myeloid leukemia (AML) that has relapsed, has been difficult to treat, or is a very difficult to treat type of AML.

AML is a cancer of the bone marrow, the spongy tissue inside the large bones of the body where blood cells are made. In AML, the bone marrow makes large numbers of immature white blood cells called blasts. These blast cells crowd out the normal cells of the bone marrow. They may flood the bloodstream and invade vital organs.

This study is for subjects that would ordinarily be offered a stem cell transplant (SCT; also known as hematopoietic cell transplantation or bone marrow transplant). AML patients might receive a stem cell transplant as part of standard therapy if:
--Chemotherapy treatment is not destroying enough of their leukemia cells. This is called -refractory AML-.
--Certain genetic factors are found in the blast cells
--AML has gone away and then comes back (called relapsed AML).

Start Date
September 24, 2009
End Date
September 24, 2019
Gender Preference
Age Group
0 - 99 years
Principal Investigator
Ayman El-Sheikh, MD
Contact Info

Julie de la Garza 319-356-3749

AAML05P1 ; acute myeloid leukemia (AML) ; cancer ; el-sheikh ; IRB#200905732 ; pediatric ; phase 2 ; phase II ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks